ORYZON reports third quarter 2026 financial results and provides corporate update

Oryzon Genomics, a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the three months ended September 30, 2026, and provided a corporate update on recent developments. 

“Since our last results update, Oryzon has continued to build the clinical evidence needed to advance our key development programs,” said Dr. Carlos Buesa, Oryzon’s Chief Executive Officer. “The three iadademstat abstracts accepted for ASH 2026 add to the growing body of clinical evidence supporting the activity of iadademstat across hematological malignancies. We are particularly encouraged by the high remission rates and promising survival results observed with iadademstat in combination with azacitidine and venetoclax in the Phase Ib ALICE-2 study in newly diagnosed AML. We look forward to presenting updated data at ASH in December.” 

“Building on the ALICE-2 findings, we are preparing to engage with the FDA on the design of ALICE-3, our planned potentially registrational Phase III trial in first-line AML,” Dr. Buesa continued. “Our objective remains to initiate the study in 2027, subject to regulatory agreement and financing. Alongside our AML 1 program, preliminary positive findings in accelerated/blast-phase myeloproliferative neoplasms and ongoing clinical evaluation in myelodysplastic syndromes are helping us explore the broader potential of iadademstat.” 

“In CNS, we continue to advance the clinical development of vafidemstat across several indications,” Dr. Buesa added. “The Phase IIb trial in schizophrenia, EVOLUTION, continues to enroll patients across several European countries, and we expect to complete enrollment in spring 2027, with topline data anticipated by the end of 2027. This readout could represent an important inflection point for the company’s CNS program. The recent authorization of the HOPE-2 Phase II study in Phelan-McDermid syndrome marks another step forward for the program. In parallel, we are progressing with preparations for the PORTICO-2 Phase III trial in BPD and plan to request a Type C meeting with the FDA. Across our portfolio, we remain focused on disciplined execution, responsible allocation of resources and the continued strengthening of our intellectual property as we prepare for the next stages of clinical development.”

To see the development of the results and progress for the third quarter of 2026, download the attached PDF.